acalabrutinib

keratin 20 ; Homo sapiens







6 Article(s)
Download
PMID
Title
Pub. Year
#Total Relationships
1 34268530 An update on acalabrutinib to treat chronic lymphocytic leukemia. 2021 Jul 1
2 34275396 Assessing the pharmacokinetics of acalabrutinib in the treatment of chronic lymphocytic leukemia. 2021 Sep 1
3 31915195 Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia. 2020 Mar 1
4 33093947 ACCEPT - combining acalabrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) for Diffuse Large B-cell Lymphoma (DLBCL): study protocol for a Phase Ib/II open-label non-randomised clinical trial. 2020 1
5 30089638 Cellular Cytotoxicity of Next-Generation CD20 Monoclonal Antibodies. 2018 Oct 1
6 28642301 The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies. 2017 Oct 1